The NKG2D downregulation in cancer patients has been correlated with high levels of circulating MICA/B molecules shed by the tumor burden [60], or with circulating mature TGF-β or to regulatory T cells expressing membrane bound TGF-β [60]–[62]. This evidence concerns the gene KLRK1 and cancer.